Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Sarepta Therapeutics announces voluntary pause all shipments of Elevidys for Duchenne muscular dystrophy in US: Cambridge, Massachusetts Wednesday, July 23, 2025, 12:00 Hrs [IST] ...

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient ...

Medicaid and ACA, the homeless crisis, children's health, 'black box' drug warnings, nutrition and SNAP, maternity care, and more.

Dow Jones Top Company Headlines at 1 AM ET: Canadian Suitor of 7-Eleven Owner Abandons Its Multiyear, $47 Billion Bid | National-Security ... Canadian Suitor of 7-Eleven Owner Abandons Its Multiyear, ...

David Solomon, Brian Moynihan and Jane Fraser speak out, joining defenders of the U.S. central bank. Santos reported a 1% rise in quarterly oil and natural gas production as it waits on a consortium ...

The Motley Fool. DATE Tuesday, July 22, 2025 at 8:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS President and ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...